David R. Bauer
Lawyers
![](/sites/default/files/styles/teaser_headshot/public/lawyer-images/25898_drbauer.jpg?itok=Y1b0J_im)
Filters
Inventiva $108 million U.S. IPO and Nasdaq listing
Davis Polk advised the representatives of the underwriters in connection with an initial public offering of Inventiva S.A.’s 7,478,261 American Depositary Shares. Aggregate gross…
Centogene $49 million follow-on offering
Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting of 2,000,000 common shares offered by Centogene and 1,500,000…
Revolution Medicines $179.4 million follow-on offering
Davis Polk advised the underwriters in connection with a public offering of 6,900,000 shares of common stock of Revolution Medicines, Inc. at $26.00 per share (which includes the…
Magenta Therapeutics $69 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $69 million follow-on offering of common stock of Magenta Therapeutics…
Editas Medicine $215.6 million stock offering
Davis Polk advised the sole book-running manager in connection with the $215.6 million common stock offering of 6,900,000 shares of common stock of Editas Medicine, Inc. The common…
Constellation Pharmaceuticals $192.5 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $192.5 million offering of common stock of Constellation…
Shockwave Medical $89.4 million stock offering
Davis Polk advised Shockwave Medical, Inc. on its SEC-registered public offering of 1,955,000 shares of common stock for an aggregate price to the public of approximately $89.4 million,…
Royalty Pharma $2.5 billion IPO
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares, which included an…
Generation Bio $230 million IPO
Davis Polk advised the representatives of the underwriters in connection with the $230 million initial public offering of 12,105,263 shares of common stock of Generation Bio Co., which…
Applied Therapeutics $100 million at-the-market offering
Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Applied Therapeutics, Inc. of shares of its common stock for up to a maximum offering…